Annual report pursuant to Section 13 and 15(d)

Note 9 - Investment in Macrophage Therapeutics, Inc. (Details Textual)

Note 9 - Investment in Macrophage Therapeutics, Inc. (Details Textual) - USD ($)		1 Months Ended			6 Months Ended	12 Months Ended
	Mar. 11, 2015	Nov. 30, 2018	Jul. 31, 2016	Mar. 31, 2015	May 31, 2016	Dec. 31, 2017	Dec. 31, 2015	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019	Aug. 31, 2018
Preferred Stock, Shares Authorized (in shares)								5,000,000		5,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)								$ 0.001		$ 0.001
Preferred Stock, Shares Issued, Total (in shares)								0		0
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								992,000
Derivative Liability, Total	$ 63,000									$ 0
Preferred Convertible Stock, Right to Exchange for Common Shares, Minimum Required Proceeds from Initial Public Offering							$ 50,000,000
Weighted Average Price Common Stock Percentage							80.00%
Future Common Stock Conversion Share Price (in dollars per share)							$ 60
Reclassification of Funds Invested						$ 200,000
Former Chief Executive Officer and President [Member]
Common Stock Shares Provided by Agreement (in shares)											1,175,000
Dr. Michael Goldberg [Member]
Convertible Preferred Stock, Percent of Shares Reserved				40.00%
Dr. Michael Goldberg [Member] \| MT [Member]
Payments to Acquire Businesses and Interest in Affiliates, Total			$ 200,000
Resignation Agreement, Subidiary Percentage Ownership After Signing											5.00%
Resignation Agreement, Shares Issued (in shares)		925,000
Resignation Agreement, Shares in Escrow (in shares)		250,000
Macrophage Therapeutics [Member]
Common Stock Shares Authorized Upon Exercise of Warrants (in shares)				1,500
Convertible Preferred Stock Shares Issued Upon Conversion, Per Unit (in shares)				1
Common Stock Warrants, Issued Upon Conversion, Per Unit (in shares)				30
Macrophage Therapeutics [Member] \| Common Stock [Member]
Common Stock as Percentage of Common Equity				1.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	300								300
Platinum [Member] \| MT [Member]
Payments to Acquire Businesses and Interest in Affiliates, Total			$ 300,000		$ 200,000
MT [Member]
Convertible Preferred Stock, PIK Coupon, Percentage			10.00%
Convertible Preferred Stock, Conversion Price, Market Cap			$ 500,000,000
Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)				50
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 50,000
Cumulative Preferred Stock [Member]
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants, Total	$ 500,000
Issuance of Stock and Warrants for Purchase Agreement, Remaining Amount							$ 2,000,000
Preferred Stock, Fair Value Put Option							113,000
Future Common Stock Conversion Denominator, Value							$ 50,000
Cumulative Preferred Stock [Member] \| Macrophage Therapeutics [Member]
Preferred Stock, Shares Authorized (in shares)				50
Preferred Stock, Shares Issued, Total (in shares)				10
Preferred Stock, Redemption Price Per Share (in dollars per share)							$ 58,320